Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset
The past decade has witnessed both a growing prevalence of head and neck cancer (HNC) driven by the human papillomavirus (HPV) [1,2] and a series of innovations [3 –7] that have enhanced the therapeutic ratio in this disease; however, survival outcomes in the United States remain suboptimal. At a national level, 5-year relative survival rates from cancers of the oral cavity, pharynx, and larynx remain at or below 66% [8], while even on recent prospective cli nical trials, patients with advanced HNC experience 3-year overall survival (OS) and progression-free survival rates that fail to exceed 76% and 62%, respectively [9].
Source: Oral Oncology - Category: Cancer & Oncology Authors: William A. Stokes, Megan Eguchi, Arya Amini, Mohammad K. Hararah, Ding Ding, Jessica D. McDermott, Cathy J. Bradley, Sana D. Karam Source Type: research
More News: Cancer | Cancer & Oncology | Fortamet | Genital Warts | Head and Neck Cancer | Human Papillomavirus (HPV) | Laryngeal Cancer | Medicare | Metformin | Oral Cancer | Oral Cavity Cancer | Pharyngeal Cancer | Toxicology | USA Health